doxorubicin or epirubicin

Phase 3Small molecule

FFudan University

doxorubicin or epirubicin is one of 17 small molecule programs targeting High Risk. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

High RiskActive, not recruiting

High RiskPhase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in High Risk

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

1 2

Taxotere

AAvyxa

Phase 3

1 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 5

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 6

Opdivo

Bristol-Myers Squibb

Phase 2

3 7

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 2

3 8

Calquence

AstraZeneca

Phase 2

1 9

Rituxan

Roche

Phase 2

1 10

Rydapt

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Active, not recruiting

High Risk

NCT02641847

Clinical

Trials by Indication[1]

High Risk1 trial

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Active, not recruiting·FFudan University·Phase 2/3·NCT02641847·503 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for doxorubicin or epirubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — doxorubicin or epirubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for doxorubicin or epirubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

doxorubicin or epirubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

High Risk1 trial

References

Drug Info

Quick Facts

Related News